clinical trial Archives - ELIAS Animal Health

ELIAS Animal Health Conducting Limb-Sparing Canine Osteosarcoma Clinical Study with Grant from Morris Animal Foundation

LENEXA, Kan., July 31, 2024 /PRNewswire/ -- ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, has initiated a new study evaluating the company’s adoptive T cell therapy—the ELIAS Cancer Immunotherapy (ECI®)—in combination with a novel adjuvant as a limb-sparing treatment for large-breed dogs suffering from appendicular osteosarcoma. The study, which is funded by a grant from Morris Animal Foundation, will be conducted in collaboration with Dr. Jeffrey Bryan and Dr. Megan Mickelson at the University of Missouri. “For dogs with appendicular osteosarcoma, amputation of the affected limb followed by chemotherapy is the typical standard of care. However, in certain cases amputation may not be appropriate,” said ELIAS Chief Medical Officer Noe Reyes, DVM. “In this study, we’re evaluating a new approach where the dog is treated with the limb-sparing surgery followed by ECI® immunotherapy.” The study will assess the safety and efficacy [...]

By jwiley|2024-07-31T07:12:52-06:00July 31st, 2024|Categories: News, Press Releases|Tags: cancer immunotherapy, canine osteosarcoma, clinical trial|0 Comments

USDA Agrees Clinical Trial Data for the ELIAS Cancer Immunotherapy (ECI®) Demonstrates Reasonable Expectation of Efficacy for the Treatment of Bone Cancer in Dogs

First-in-class adoptive cell therapy for treatment of osteosarcoma, a deadly form of bone cancer in dogs OLATHE, Kan., Jan. 17, 2024 /PRNewswire/ -- ELIAS Animal Health, a leading companion animal cancer therapeutics company, today announced the U.S. Department of Agriculture Center for Veterinary Biologics has determined that the data from the company’s ECI-OSA-04 pivotal combined safety and efficacy study demonstrated a reasonable expectation of efficacy, a critical milestone in the licensure pathway. Cancer is the leading cause of death in dogs over the age of two and represents a significant unmet medical need in veterinary medicine. This two-arm field safety and efficacy study (n=100) is one of the largest clinical trials conducted in canine cancer and the first of its kind to evaluate a state-of-the-art adoptive cell therapy as a treatment for cancer in dogs. The ELIAS Cancer Immunotherapy (ECI®) works by conditioning the immune system to recognize a patient’s [...]

By jwiley|2024-02-27T19:07:55-06:00January 17th, 2024|Categories: News, Press Releases|Tags: adoptive cell therapy, cancer immunotherapy, canine osteosarcoma, clinical trial, ECI, immunotherapy, killer t cell|0 Comments

New Clinical Trial Will Evaluate Combination Therapy to Treat Canine Lymphoma

After successfully concluding a clinical trial for canine osteosarcoma, ELIAS Animal Health is focused on continuing to push forward in the fight against cancer with a new clinical trial involving combination therapy to treat lymphoma in dogs. The pilot study, which is currently underway, will evaluate ELIAS Cancer Immunotherapy (ECI®) in combination with VCAA (L- asparaginase, vincristine, cyclophosphamide, and doxorubicin) chemotherapy to treat lymphoma in dogs. All trial participants will be treated at a single investigator site for this preliminary study. Prevalence of Lymphoma in Dogs Canine lymphoma is a fairly common type of cancer in dogs. In an article published by VCA Animal Hospitals, authors Malcolm Weir, DVM, MSc, MPH and Catherine Barnette, DVM the disease accounts “for 15-20% of new cancer diagnoses in dogs. It is most common in middle-aged and older dogs, and several breeds are predisposed...” Overview of the Clinical Trial Protocol for Canine Lymphoma Patients [...]

By Tammie Wahaus, CEO & Founder|2023-11-02T13:40:15-06:00November 2nd, 2023|Categories: Blog, News|Tags: cancer immunotherapy, canine cancer, clinical trial, lymphoma|0 Comments

Oncolytic Virotherapy in Veterinary Medicine

ELIAS Animal Health previously announced it has in-licensed an oncolytic vaccinia virus treatment for pet animals from Genelux Corporation. The agreement grants ELIAS the worldwide right to development and commercialization of V-VET1 for the diagnosis, prevention and treatment of cancer in veterinary medicine. Check out some of the most frequently asked questions about this agreement and what we plan to do with the technology. What is V-VET1? V-VET1 is Genelux Corporation’s clinical-stage animal health product candidate. It is a vaccinia viral strain that selectively replicates in cancer cells to ultimately cause cell death (apoptosis). Who is Genelux Corporation? Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for human patients suffering from aggressive and/or difficult-to-treat solid tumor types. Learn more about Genelux and their technology at www.genelux.com. What is an oncolytic virus? An oncolytic virus is a virus that can infect and kill cancer [...]

By jwiley|2023-10-13T13:18:07-06:00October 13th, 2023|Categories: Blog|Tags: clinical trial, oncolytic virus, translational medicine|0 Comments

How Long-Term Patient Registries Support Better Cancer Care

Our mission at ELIAS Animal Health is to improve cancer treatment outcomes in veterinary patients through the advancement of innovative therapies. To do that, it is imperative to understand the long-term outcomes of dogs who undergo the ELIAS Cancer Immunotherapy (ECI®). Following our randomized controlled trial (RCT) for canine osteosarcoma, we recently launched a long-term patient registry which will collect both long-term survival and quality of life data on dogs who participated in our clinical trials or received ECI outside of clinical trials. What Are Long-Term Patient Registries? Long-term patient registries allow us to observe real-world ongoing outcomes after clinical trials have concluded. ELIAS’ patient registry will provide insight into the quality-of-life dogs experience post-treatment, help us understand the long-term impact of ECI, and deliver data points that may (or may not) impact our understanding of the patient’s outcome. It will also inform our future product development. Specifically, the registry [...]

By jwiley|2023-04-26T14:52:37-06:00April 26th, 2023|Categories: Blog|Tags: canine osteosarcoma, clinical trial, patient registry|0 Comments

One Health: Leveraging the Intersection of Health Across Our World

January is One Health Awareness Month, which recognizes and promotes the "interconnectedness of the health of people, animals, and the environment." (Forbes.) ELIAS Animal Health was founded to apply the progress that has been made in fighting human cancers in the veterinary space, and then share the findings with our human health counterparts. We follow a collaborative, interdisciplinary approach, aligned with the One Health philosophy about the connections and correlations between the health of people, animals, and the environment. Human and canine cancers share similarities, so research on either side can impact and support the other: TVAX Biomedical is launching a glioblastoma study in the near future. ELIAS’ origins came from the early work and research conducted by TVAX. TVAX and Genelux Corporation, a clinical stage immunotherapy company focused on developing oncolytic virus therapies for humans, have formed a joint venture known as V2ACT Therapeutics™, LLC that will focus on [...]

By Tammie Wahaus, CEO & Founder|2023-01-24T12:56:03-06:00January 10th, 2023|Categories: Blog|Tags: cancer, clinical trial, one health|0 Comments

ELIAS Animal Health Launches Clinical Trial Of Cancer Immunotherapy Treatment For Canine Oral Melanoma

Olathe, Kan., August 31, 2021 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a pilot study of its adoptive T cell therapy combined with surgery and radiotherapy, if indicated, for dogs diagnosed with oral malignant melanoma, a highly metastatic disease and the most common form of oral cancer seen in dogs. Melanoma is widely believed to be chemo-resistant and in this study the adoptive T cell therapy will be administered instead of chemotherapy. This clinical trial will enroll dogs that have been newly diagnosed with oral melanoma but have not yet been treated for their cancer. It is a multi-center, single-arm study with no randomization. ELIAS is providing financial assistance that will substantially cover costs of participation and treatment in the trial. A list of participating sites can be found on the website. Adoptive T cell therapy is [...]

By jwiley|2022-01-08T14:27:30-06:00August 31st, 2021|Categories: News, Press Releases|Tags: clinical trial, oral melanoma|0 Comments

ELIAS Animal Health Expands Clinical Trial of Immunotherapy Treatment for Cancer in Dogs

Ten sites now participating in trial of alternative treatment to chemotherapy for canine osteosarcoma Olathe, Kansas, Nov. 12, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announces that 10 investigation sites across the U.S. are now participating in the pivotal trial of ELIAS cancer immunotherapy (ECI®). This marks an expansion of the study ELIAS initiated in May to pursue licensure of ECI treatment combined with surgery as an alternative to chemotherapy for dogs diagnosed with osteosarcoma, a deadly form of bone cancer. The geographical areas served by the clinical trial investigation sites include Southern California, the Intermountain Region, the Desert Southwest, the Chicago metropolitan area, North Texas, the Carolinas, and the Mid-Atlantic region, which includes Southeast Pennsylvania, Virginia and Washington D.C. ELIAS will continue recruiting sites to further expand pet owner access to the trial. To learn more about participating [...]

By jwiley|2022-01-08T14:27:21-06:00November 12th, 2020|Categories: News, Press Releases|Tags: canine osteosarcoma, clinical trial|0 Comments

Clinical study results demonstrate long term survival in dogs with osteosarcoma treated with ELIAS cancer immunotherapy

Results of a clinical study of the ELIAS cancer immunotherapy (ECI®) protocol demonstrated that the administration of an autologous cancer cell vaccination, adoptive T cell transfer, and interleukin‐2 resulted in long‐term survival for dogs with osteosarcoma, a deadly form of bone cancer. The article, published in the Journal of Veterinary Internal Medicine by researchers from the University of Missouri, describes the 14-dog single-arm prospective study and discusses the results. The objective of the study was to evaluate the hypothesis that dogs could be treated safely with the ECI protocol, which includes administration of ex vivo activated T cells, and experience survival times twice that of amputation alone. Median survival time for dogs in the study was 415 days, with one dog developing metastasis then experiencing spontaneous complete remission. Read the full study results. In May, ELIAS Animal Health announced the initiation of a follow-up study to pursue licensure of ECI [...]

By jwiley|2020-07-27T10:26:01-06:00July 14th, 2020|Categories: News|Tags: cancer immunotherapy, canine osteosarcoma, clinical trial, results, university of missouri|0 Comments

ELIAS Animal Health announces clinical trial launch: ECI-OSA-04 for the treatment of canine osteosarcoma

Olathe, Kan., May 28, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a follow-up study to pursue licensure of the ELIAS cancer immunotherapy (ECI®) treatment combined with surgery as an alternative to chemotherapy for dogs diagnosed with osteosarcoma, a deadly form of bone cancer. In a preliminary clinical study, the median survival time was 415 days, compared to 270-300 days for traditional chemotherapy treatments, suggesting that ECI holds the potential to significantly improve survival times and quality of life for the canine patient. This clinical trial will enroll dogs that have been diagnosed with osteosarcoma, but have not yet been treated for their cancer. It will be a two-arm study with a 1:1 randomization comparing ECI and carboplatin, a type of chemotherapy. ELIAS is providing financial assistance that will substantially cover costs of participation and treatment [...]

By jwiley|2020-06-16T10:15:26-06:00May 28th, 2020|Categories: News|Tags: cancer immunotherapy, canine osteosarcoma, clinical trial|0 Comments